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Abstract 
 
The mTOR pathway was discovered in the late 1970s after the compound and natural 
inhibitor of mTOR, rapamycin was isolated from the bacterium Streptomyces 
hygroscopicus. mTOR is serine/threonine kinase belonging to the phosphoinositide 3-
kinase related kinase (PIKK) family. It forms two distinct complexes; mTORC1 and 
mTORC2. mTORC1 has a key role in regulating protein synthesis and autophagy whilst 
mTORC2 is involved in regulating kinases of the AGC family. mTOR signaling is often 
over active in multiple cancer types including breast cancer. This can involve mutations 
in mTOR itself but more commonly, in breast cancer, this is related to an increase in 
activity of ErbB family receptors or alterations and mutations of PI3K signaling. 
Rapamycin and its analogues (rapalogues) bind to the intercellular receptor FKBP12, 
and then predominantly inhibit mTORC1 signaling via an allosteric mechanism. 
Research has shown that inhibition of mTOR is a useful strategy in tackling cancers, 
with it acting to slow tumor growth and limit the spread of a cancer. Rapalogues have 
now made their way into the clinic with the rapalogue everolimus (RAD-001/Afinitor) 
approved for use in conjunction with exemestane, in post-menopausal breast cancer 
patients with advanced disease who are HER-2 negative (normal expression), hormone 
receptor positive and whose prior treatment with non-steroidal aromatase inhibitors has 
failed. Testing across multiple trials has proven that everolimus and other rapalogues 
are a viable way of treating certain types of cancer. However, rapalogues have shown 
some drawbacks both in research and clinically, with their use often activating 
feedback pathways that counter their usefulness. As such, new types of inhibitors are 
being explored that work via different mechanisms, including inhibitors that are ATP 
competitive with mTOR and which act to perturb signaling from both mTOR complexes.  
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Overview of mTOR Signaling 
 
The mTOR pathway was not uncovered until the serendipitous discovery of rapamycin in 
the late 1970s. This compound isolated from the bacterium Streptomyces 
hygroscopicus and named from the island on which it was discovered (Easter Island/ 
Rapa Nui), was found to have strong anti-fungal, immune-suppressant and anti-cancer 
properties. Rapamycin was found to inhibit two yeast proteins named the target of 
rapamycin (TOR) 1 and 2, with the single mechanistic (previously mammalian) TOR 
(mTOR) then later uncovered. From this point, the mTOR pathway has been built around 
this central protein which has been shown to be a critical regulator of many important 
cellular processes1-8. 
 
mTOR belongs to the phosphoinositide 3-kinase related kinase (PIKK) family and is 
expressed in most mammalian cells2,9, causing an increase in cellular protein mass and 
growth and inhibiting autophagy, with it generally acting as a cellular sensor to 
nutrients and growth factors, as well as being an important effecter pathway of PI3K 
signalling10.  
 
mTOR and mTOR Complexes (mTORCs) 
 
Residues 1-1375 of mTOR are not as well defined as the rest of the protein, but 
predictive modelling techniques and information from related kinases suggest this N-
terminal half of the protein consists mostly of HEAT repeats11. The remaining structure 
of the protein is well defined, by crystal structure, consisting of the FAT, FRB, kinase and 
FATC domains. ATP binds within the kinase domain (KD), whilst rapamycin-FKBP12 
binds in the FRB domain12,13.  
 
mTOR acts in one of two protein complexes; mTORC1 or mTORC2 with a combination of 
common and unique components (Figure 1). mLST8 binds to mTOR at the kinase 
domain C-lobe and data suggest that mLST8 is needed for proper mTOR kinase 
function as well as helping to stabilize the interaction between mTOR and raptor, in 
mTORC114. Extremely important to mTORC1 function is raptor, a 149kDa protein that is 
usually found in a complex with mTOR, binding to the mTOR HEAT repeats.  
 
The sub-complex of Tel2 and Tti1 act as a scaffolding structure to both mTOR 
complexes and other PIKK proteins; Tel2 also binds to mTOR via the HEAT repeats15,16, 
with heat shock protein 90 (Hsp90), acting as a chaperone for the Tel2-Tti1 
complex17,18. DEPTOR is also an inhibitor of mTOR function, binding to mTOR on its FAT 
domain via DEPTOR’s PDZ domain19, with research showing an increase in 
phosphorylation of mTOR targets after DEPTOR knock down20. DEPTOR regulation is via 
its degradation, with mTOR signaling triggering the phosphorylation of DEPTOR, leading 
to its ubiquitination by the E3 ligase, SCFβTRCP 21,22.  
 
mTORC1: Raptor acts as a scaffold for mTORC1, not having catalytic activity itself, but 
is required for full activation of mTORC125-27. The mTOR complexes also contain sub-
units that act as inhibitors of mTOR function. Unique to mTORC1 is the proline-rich Akt 
substrate of 40 kDa (PRAS40), which binds to the complex via raptor. PRAS40 is 
believed to have an inhibitory effect on mTORC1 function, with most studies showing 
increased mTORC1/mTOR activity in the absence of PRAS40, although this may be 
tissue specific28,29; PRAS40’s inhibitory effect is speculated to be due to the inhibition 
of substrate binding30. 
  
 
mTORC2: mTORC2 is less studied than mTORC1, but many years of research have 
begun to elucidate more components and functions of the second complex. Whilst 
mTORC2 has a very different set of functions to mTORC1, it does contain many of the 
same subunits in a similar role; these include mTOR itself, mLST8, DEPTOR and Tel2-
Tti1. A defining component of mTORC2 is rictor, which forms the basis of this second 
complex, also binding to the HEAT repeats of mTOR. Like mLST8, rictor is needed for 
mTORC2 catalytic activity and also acts as a scaffold for many proteins in the 
complex23,31,32. Research by Martin and colleagues24 suggested that rictor may act as a 
point of binding for Hsp70, with this study also implicating Hsp70 as a key regulator of 
mTORC2 function.  
 
mSIN1 is an mTORC2 scaffold protein, which binds to the complex via rictor. mSIN1 is 
thought to be required for proper mTORC2 formation, with it stabilizing the mTOR-rictor 
interaction. mTORC2 targets such as Akt also show markedly decreased 
phosphorylation without mSIN1, showing mTORC’s role in regulating kinase activity of 
the complex33,34. Protor 1 and 2 are the last major components of mTORC2. Protor-1 
and 2 bind to rictor within the complex, but are not needed for stabilisation28,35,36. 
Protor-1 appears to play a role in mTORC2 activity towards one of its substrates, SGK1, 
with a markedly decreased phosphorylation of this target in protor-1 absence36,37. Like 
protor-1, protor-2 also appears to modulate mTORC2 in a substrate specific manner; 
with work by Gan and colleagues38 showing protor-2 may suppress mTORC2 
phosphorylation of PKC. 
 
Upstream Signaling 
 
mTOR itself is phosphorylated at multiple sites, including a level of auto-
phosphorylation at Ser248139, with some of this phosphorylation induced by growth 
factor signaling. Research suggests many of these phosphorylated sites (such as 
Ser2448) increase mTOR activity and may be needed for proper mTORC1 function40-43. 
Intriguingly, work by Copp and colleagues44, suggested that Ser2481 phosphorylation of 
mTOR could act as a good biomarker for intact mTORC2 complexes as mTORC2 had 
predominantly Ser2481 phosphorylation, whilst mTORC1 had predominantly Ser2448 
phosphorylation.  
 
mTORC1: There are a variety of upstream pathways which control mTORC1 activation, 
including growth factor signaling, amino acid levels, cellular energy levels and stress 
(reviewed by Sengupta and colleagues45). The tubular sclerosis complex (TSC) is a 
convergence point for many of these upstream factors and is a key regulator of 
mTORC1 activity. The complex consists of TSC1 (also known as Hamartin), TSC2 (also 
known as Tuberin) and TBC1D746, and functions via the Rheb GTPase47,48. Lysosomal 
localization is important for mTORC1 activation with recent research suggesting that 
the phosphorylation of TSC actually causes TSC to dissociate from the lysosome, away 
from mTORC1 and Rheb, activating mTORC149.  
 
The PI3K pathway is a key upstream regulator of mTORC1, via TSC. Growth factors such 
as IGF-1 and insulin activate phosphoinositide 3-kinase (PI3K), which in turn generates 
PIP3 from membrane-bound PIP2. This recruits downstream effectors such as PDK1 and 
Akt (also known as protein kinase B/PKB) via their PH domains. Akt can then be 
activated via phosphorylation by PDK1 on Thr308 and Ser47350. Akt is a critical 
regulator of TSC, with active Akt phosphorylating TSC2 at multiple sites, to weaken its 
  
interaction with TSC1 and destabilize the TSC2 protein. This in turn activates mTORC1, 
as TSC2 can no longer act as the GTPase activating protein (GAP) for Rheb51,52. Akt can 
also regulate mTORC1 activity by phosphorylating PRAS40, causing it to bind to 14-3-3 
proteins, thus relieving its inhibitory effect on the complex29.  
 
The Ras-Erk MAPK pathway can also lead to downstream activation of mTORC1. Once 
Erk is activated, it can directly phosphorylate and inactivate TSC2 on Ser66453,54 or 
phosphorylate p90 ribosomal S6 kinase 1 (RSK1), leading to TSC2 inactivation via 
phosphorylation at Ser179855.  
 
Amino acid levels are critical regulators of mTORC1 function; increased levels of amino 
acids result in mTORC1 activation, and growth factors are unable to activate mTORC1 
without the required level of amino acids42,56. The Rag GTPases are central to this 
regulation, acting as dimers of either RagA or B dimerized with either Rag C or D. In its 
active state, the complex binds raptor, localizing mTORC1 to the lysosome, and bringing 
it into contact with Rheb42,57.  
 
How the cell exactly translates amino acid levels to mTORC1 activation is not well 
understood, but many proteins are now being revealed to have roles in this amino acid 
sensing. The molecular pump v-ATPase is required for activation of mTORC1, with it 
directly interacting with the ragulator complex and in turn amino acids directly regulate 
this interaction58. Of interest is work by Pena-Llopis and colleagues59 which showed 
that mTORC1 may be involved in positive feedback, with mTORC1 activation increasing 
v-ATPase expression. It is probable that the full extent of the amino acid sensing 
‘machinery’ (in relation to mTORC1) is yet to elucidated, but current candidates include 
MAP4K360, SLC38A961,62 and PAT1 (SLC36A1)63. 
 
Cellular energy levels also regulate mTORC1 activity, with low energy generally 
inhibiting mTORC1, and reducing protein synthesis. This is mainly via cellular levels of 
AMP decreasing when ATP is low, activating AMPK, and causing raptor phosphorylation 
and subsequent binding to 14-3-3 proteins, sequestering it away from mTORC164. 
Activated AMPK also phosphorylates TSC2 on Thr1227 and Ser1345 to activate (rather 
than inactivate, as is the case when Akt phosphorylates TSC2 on Ser 924 and Thr1518) 
the TSC to further decrease mTORC1 signalling51,65. Since downstream mTORC1 
activates protein synthesis it is important the cell only activates mTORC1 signaling 
when it has the required resources, such as ATP/energy and amino acids. Lower cellular 
oxygen levels and other cellular stresses also reduce the activity of mTORC1. For 
example stress such as hypoxia can induce regulated in DNA damage and development 
1 (REDD1), which inhibits mTORC1 function66.  
 
mTORC2: Although knowledge of mTORC2 signaling is less defined than for mTORC1, 
research is beginning to fill in gaps in our knowledge. It has been known for a while 
that, like mTORC1, mTORC2 is activated by growth factors such as insulin and IGF-167; 
although only mTORC2 complexes containing mSIN1 isoforms 1 and 2 (not 5) are 
activated by insulin68. Recent research has shown that mSIN1 is a critical mediator for 
growth factors to activate mTORC2, with PI3K signaling linking the two. Membrane 
bound PIP3 binds mSIN1 via its PH domain, relieving its interactions with mTORC2, 
thus activating it69,70. This is in contrast to earlier findings which show that mSIN1 is 
needed for mTORC2 activity33,34. These seemingly conflicting reports highlight the 
relatively poor understanding on the precise mechanism of mTORC2 action and 
activation. 
  
 
Active PI3K signaling promotes mTORC2 activation and binding to ribosomes, possibly 
as a mechanism to limit its activation only in growing cells with a high enough ribosome 
content71. Remarkably, whilst the TSC inhibits mTORC1 function, it is suggested that, in 
at least some cell lines (including the breast cancer cell line MCF7), the complex is 
needed for full mTORC2 activation as well as having a physical interaction with 
mTORC2, independent of its function with rheb72.  
 
Considering that DEPTOR was discovered relatively recently, it is possible that there are 
still mTOR complex components that have not been discovered. If this is the case, it 
may also explain why there are seemingly conflicting conclusions on the role some of 
these proteins, as there could be as yet undiscovered interactions. Research by Luo and 
colleagues73 found that rapamycin can inhibit mSin1phosphorylation independently of 
mTORC1 or 2 (raptor and rictor are not required), but the mechanism of inhibition does 
involve mTOR and mLST8. This again suggests that there may be further mTOR 
complexes yet to be discovered, that explain the observed effect.  
 
Downstream Signaling 
 
mTORC1: The molecular and cellular effects of mTORC1 activation are well 
characterized, with a number of processes regulated from this point. Protein synthesis 
is critically regulated by mTORC1 with mTORC1 phosphorylating both eIF4E- binding 
proteins (4E-BPs) and S6 kinases including S6K2 and the multiple S6K1 isoforms.  
p70-S6K1 is first phosphorylated on multiple sites subsequently allowing 
phosphorylation of Thr389 by mTORC1, followed by phosphorylation on Thr229 by 
PDK1 to fully activate the kinase74. S6K1/2 then phosphorylates multiple proteins 
involved in the translation machinery. S6K1 activation is also believed to promote 
transcription via its interactions with transcription factors such as estrogen receptor α 
(ERα), as well as regulating ribosomal gene transcription75,76. Unsurprisingly negative, 
feedback loops exist along the mTORC1 axis involving S6K1, with the active protein 
both repressing the expression of IRS-1 and phosphorylating it on inhibitory serine 
residues77. mTORC1 also serves to feedback to mTORC2, with S6K directly 
phosphorylating rictor, which may serve to control activation of Akt78.   
 
mTOR phosphorylation of 4E-BP1 on sites including Thr 37, 46 and 70 and Ser 65 by 
mTOR, prevents the inhibitory action of the 4E-BPs on eIF4E to allow the latter to 
initiate cap-dependent translation79,80.   
 
Autophagy is generally not needed when the cell is healthy with a plentiful nutrient 
supply activating mTORC1, and inactivating autophagy through phosphorylation of 
kinases ULK1/2 and ATG1381-83. The ULK complex also cross-talks with the beclin1 (or 
VSP34) complex. mTORC1 can phosphorylate a member of this complex called 
AMBRA1, to reduce ubiquitination of ULK1 by the VSP34 complex protein, TRAF6. 
Unusually, rather than destroy the protein, this ubiquitination actually increases its 
activity84. As AMPK reduces both mTOR signaling, and increases ULK phosphorylation it 
increases autophagy in cellular stress, in opposition to the mTOR pathway85.  
 
Aside from these functions, mTORC1 is also partially involved in regulating other 
important cellular processes related to metabolism, such as glycolysis via hypoxia 
inducible factor (HIF1α) induction86-88, lipid metabolism89, and de novo synthesis of 
pyrimidines90.  
  
 
mTORC2: mTORC2 regulates the activity of several proteins belonging to the AGC 
kinase family and it can, in one sense, be thought of as ‘upstream’ of mTORC1 as it is 
one of many regulators of the AGC kinase, Akt. Akt has many downstream effectors of 
its own, increasing proliferation, cellular growth (e.g. its role in mTORC1 activation via 
TSC2), cell survival, angiogenesis and metabolic processes91. mTORC2 directly 
phosphorylates Akt on Ser473, which is required for its maximal activation92. However 
mTORC2 is not the only activator of Akt, with Akt substrates such as FoxO1 being 
impaired by mTORC2 depletion, when others like GSK3β were not affected33,93.  
 
mTORC2 also phosphorylates the AGC kinase SGK1, thereby contributing to the 
regulation of proliferation and apoptosis via FoxO3a94, ion channels such as Na+95 and 
regulating differentiation in cell types such as TH1 and TH2 immune cells96. mTORC2 
can affect cellular shape, structure and morphology, specifically by altering the actin 
cytoskeleton, with part of this control, at least, down to mTORC2 regulation of PKC, 
another member of the AGC kinases31,32,97. 
 
As well as associating with ribosomes71, mTORC2 also associates with the endoplasmic 
reticulum (ER) sub-compartment called the mitochondria-associated ER (MAM). This 
sub compartment is a key part of calcium and lipid transfer, with mTORC2 deficiency 
directly leading to a disruption of these functions and MAM integrity98.  
 
mTOR and Breast Cancer 
 
Looking at the multitude of cellular events mTOR complexes help regulate, it is of no 
surprise that the activation of mTOR signaling is associated with cancer and is 
perceived as being oncogenic. The activation of mTOR complexes will give tumors a 
vast growth advantage, with an increased amount of protein synthesis, as well 
increased inhibition of autophagy. Thus whilst growing at an increased rate, these cells 
are also less likely to die. Research has generally shown that activated mTOR signaling 
leads to an increase in tumor progression and often a decrease in patient survival99,100. 
mTOR expression correlates for a worse prognosis in breast cancer101,102 with work by 
Walsh and Colleagues103 showing that phospho-mTOR was more common in triple 
negative breast cancers. Despite the fact that mTORC2 signaling can increase 
oncogenic signals via Akt and mTOR signaling, research has suggested that rictor 
expression, which is required for mTORC2 signaling, is actually lower in breast tumors 
compared to normal breast tissue102. This could suggest that mTORC1 signaling is 
more oncogenic than mTORC2 signaling or that rictor is required in very specific 
amounts for mTORC2 signaling; with too much or too little ultimately inhibiting the 
mTORC2 arm.  
 
In terms of how the mTOR pathway is altered in cancer, it is found that the majority of 
alterations and mutations lie upstream of mTOR itself and lead to an increased 
activation of mTOR signaling. Common in many cancers, are alterations to PI3Ks, which 
are key activators of mTOR via Akt and TSC1/2 and have been shown to cause over 
activation of mTOR signalling104. Activating mutations in the PIK3CA gene (which 
encodes a subunit of PI3K) are common in breast cancer, with the mutations usually 
centered in kinase and helical domains105. Other common mutations upstream of 
mTOR occur in AKT, with altered or mutated AKT and loss of PTEN detected in breast 
cancer106. Familial mutations in PTEN Cowden Syndrome also increases the risk of 
developing sporadic cancers of the breast, thyroid and kidneys107.  
  
 
Mutations and alterations of core mTOR components (involved in either of the two 
mTOR complexes) are by and large a lot rarer than upstream mutations, but have still 
been noted in cancers, within the last few years. With the availability of more powerful 
sequencing technology combined with large online databases containing sequencing 
data, many research groups have been able to identify mutations in mTOR itself108-110. 
These pieces of research have shown that mutations have occurred in a variety of 
cancer types and whilst these alterations occur along the length of mTOR (figure 2), a 
high frequency have been found in domains such as the FAT and FATC domains. Since 
the latter forms part of the kinase domain, it is no surprise that many of the mutations 
identified in this research resulted in either increased mTORC1 or 2 activity. Some 
mutations in MTOR also showed decreased binding to the inhibitor DEPTOR, possibly 
due to mutations in the FAT domain108. 
 
mTOR and ER: The activation of mTOR signaling in cancer cells is associated with 
resistance to multiple drug therapies, especially in breast cancer where this affect is 
well studied. Tamoxifen is a selective estrogen receptor modulator (SERM), binding to 
the nuclear ERα, to block it’s binding to estrogen and therefore block receptor 
activation. A majority of breast cancer patients are estrogen receptor positive and so 
often receive drugs like tamoxifen (if pre-menopausal), but resistance to them is a 
common issue111. Whilst there are multiple mechanisms behind this resistance, mTOR 
appears to have a major role, with the mTOR pathway phosphorylating ERα at Ser118, 
making it hyper sensitive to activation and less likely to bind tamoxifen112. Research 
has shown that in the long term, breast cancer cells may use the PI3K/Akt/mTOR axis 
to escape dependency from ER signaling and thus increase their resistance to 
tamoxifen113. Inhibiting the mTOR pathway has been shown to also help re-sensitize 
cells to anti-cancerous effects of tamoxifen114.  
 
mTOR and HER: Also key in breast cancer are the relative expression of ErbB/HER 
receptors. EGFR appears to be relatively commonly expressed, with 17.1% of a study of 
706 invasive ductal breast carcinomas, showing over-expression of EGFR115; expression 
of EGFR appears to correlate well with HER-2 over-expression, suggesting a therapeutic 
benefit to inhibiting both types of receptor116. 
 
Since HER family receptors can activate PI3K-mTOR signaling, HER-2 expression is 
important in the over-activation of mTOR signaling in breast cancer. HER2 is amplified 
in upwards of 15-20% of all breast cancers, which can result in a nearly 100-fold 
increase of protein expression. Its status as a key biomarker comes from that fact that 
HER-2 expression correlates with a much poorer prognosis and a generally more 
aggressive cancer117,118. mTOR signaling has been linked with resistance to HER-2 
therapies in breast cancer, such as with the antibody based drug trastuzumab119, and 
the dual EGFR (HER-1) and HER-2 inhibitor lapatinib120. Activation of mTOR signaling in 
tumor cells after ErbB inhibition can arise as a result of mutations in the PI3K pathway 
and the use of other growth factor receptors like IGF-1R (in which HER-2-IGF-1R dimers 
can form), contributing to drug resistance121,122. It is therefore of no surprise that in vivo 
studies have shown an increased effect when rapamycin is used with trastuzumab123. 
 
mTOR-Targeted Therapies  
 
Rapalogues: Since its identification, over four decades ago, rapamycin has been studied 
as a therapy for a wide variety of diseases. With it being the first mTOR inhibitor to be 
  
discovered, work on rapamycin led to a new field devoted to elucidating compounds 
that inhibited the mTOR pathway. The first, and currently most widely used, set of 
compounds, are rapamycin and its analogues that are more commonly known as 
‘rapalogues’. Rapamycin (structure shown in Figure 3), also known as sirolimus, is a 
macrocyclic lactone, isolated from the bacterium Streptomyces hygroscopicus initially 
noted for its strong anti-fungal effect8. It was later found to have strong 
immunosuppressive affects, blocking T-cell activation3 and in 1999 was originally 
approved for use as an immunosuppressant drug in the USA124; it is used in procedures 
such as kidney transplantation, to reduce rejection, risk of infections and also to lower 
the incidence of post-surgery cancer125. 
 
Due to its inhibitory effect on mTOR, and thus cellular growth, rapamycin was explored 
as an anti-cancer agent. It was shown to inhibit cellular proliferation and/or be effective 
in several types of cancer including pancreatic126, colon4, rhabdomycosarcoma127 and 
breast124. However, rapamycin has on the whole not been taken forward for cancer 
therapy due to its poor pharmacokinetic properties, including its low solubility128.  
 
Rapamycin derivatives/rapalogues have since been developed to tackle these issues, 
opening up new avenues for treatment for not only cancers but a variety of other 
conditions. These include everolimus (RAD-001), temsirolimus (CCI-779), ridaforolimus 
(deforolimus, AB23573) and zotarolimus (ABT-578).  Details of these rapalogues can be 
found in table 1.  
 
Rapalogue Mechanism of Action: Rapalogues all inhibit mTOR, using the same 
mechanism of action, which involves the intracellular receptor and immunophilin, 
FK506 binding protein 12 kDa (FKBP12). FKBP12 binds FK506, and mediates 
immunosuppressive actions via its alteration of the phosphatase calcineurin, with 
FKBP12 able to regulate cellular levels of Ca2+147,148.  
 
FKBP12 was shown early on to bind rapamycin, and mediate its action through its 
binding to mTOR, causing an inhibition of cell cycle progression2. The FKBP12-
rapamycin complex binds to mTOR at the FRB domain, acting through allosteric 
inhibition and conformational changes in mTOR and mTORC113,149,150, resulting in 
decreased interaction between mTOR and raptor151 which could inhibit the 
phosphorylation and activation of the major mTORC1 downstream targets including 
S6K and 4E-BP1. However, further, more in depth research about events post-rapalogue 
treatment has revealed a differentiation in the amount of inhibition actually seen on 
each mTORC1 substrate, with the levels of inhibition of 4E-BP1 phosphorylation 
compared to S6K varying greatly over time and between cell types152,153. Interestingly, 
the level of auto-phosphorylation on mTOR in mTORC1 (but not mTORC2) on Ser2481 is 
also greatly reduced upon rapamycin treatment39.  
 
Rapalogues were long thought to only inhibit only mTORC1 complexes and their 
downstream effectors, with evidence at the time supporting this theory31. However 
more in depth study of rapamycin’s effect on mTORC2 has revealed that prolonged 
treatment does in fact inhibit mTORC2 as well as mTORC1, with rapamycin treatment 
directly affecting the assembly of mTORC2 components, including rictor. Therefore 
rather than binding directly to mTORC2, like it does mTORC1, the FKBP12-rapamycin 
complex binds mTOR and then over time stops the formation of new mTORC2 
complexes154-156.  
 
  
At a cellular level, rapalogues show many effects useful for the treatment of cancer. 
Due to the inhibition of protein translation, growth of cells can be severely affected, 
limiting progression through the cell cycle, usually at the G1 phase, and ultimately 
inhibiting tumor growth2,157. Rapalogues have shown this growth inhibitory effect in a 
wide variety of cells, with rapamycin inhibiting the growth of cancer cells including 
prostate158, small cell lung159 and rhabdomycosarcoma127. Acting through similar 
mechanisms, everolimus has been shown to inhibit the growth of cancer cells including 
breast160, acute lymphoblastic leukemia (ALL)161 and oral squamous cell carcinoma 
(OSCC)162.  
 
Rapalogues are also able to induce autophagy in certain cancer types, including breast 
cancer163 and malignant gliomas164 as well as having an apoptotic effect on human 
dendritic cells165. Whilst this increase in autophagy is not surprising due to mTORC1 
control over autophagy initiation and ULK1/2 phosphorylation81, it is not widely noted in 
cancer types, where cell cycle arrest and growth inhibition appear to be the primary 
cellular means by which rapalogues act. Everolimus, like rapamycin, can also cause an 
increase in apoptosis within breast cancer and rhabdomycosarcoma cell cultures166-168. 
 
However, inhibiting mTOR signaling in this manner has its drawbacks in terms of the 
desired molecular effect, highlighting possible issues when applying rapalogues in a 
clinical setting. Usually, negative feedbacks loops exist to perturb over-active mTOR 
signaling, with S6K inhibiting IRS-1 to reduce mTOR activation via insulin/IGF-1 
signalling77,169. Thus, in rapalogue treatment, cells may actually be more sensitive to 
PI3K-mTOR activation via growth factor signals such as insulin170. The inhibition of 
mTORC1 (on a short term scale) seems to also favor the formation of mTORC2 
complexes, shifting mTOR signaling burden from one arm to the other171. In line with 
this, and the fact that mTORC2 leads to increased Akt phosphorylation at Ser47332, 
rapalogue treatment appears to lead to increased Akt activation. This not only further 
increases upstream signals activating the mTOR pathway but also increases the 
activation of various survival pathways associated with Akt activation172. Everolimus 
and other rapalogues, have been shown to abolish the negative feedback on IRS-
1/insulin signaling, up-regulating and further activating growth factor signaling via PI3K 
and Akt in both cancer cell cultures and patient samples173,174. Patients with metastatic 
cancer have also shown up-regulation of other signaling pathways including MAPK 
signaling, when treated with everolimus175. 
 
Clinical Applications of Everolimus and Rapalogues in Breast Cancer 
 
Rapamycin: Many rapalogues have now made their way into clinical use, or are being 
explored for therapeutic in breast cancer patients. Whilst it may be the ‘founding 
member’ of the rapalogues, rapamycin not used on a large scale in cancer therapeutics 
and is unlikely to have future impact as a sole agent. Whilst not yet approved for use in 
breast cancer, it has shown some small efficacy in the treatment of this disease when 
used as a combination therapy. Phase II trial data in HER-2 positive patients suggested 
adding rapamycin may benefit trastuzumab treatment176 and that the combination of 
resveratrol with rapamycin may stop Akt feedback activation in breast cancer cells177. 
 
Temsirolimus: Temsirolimus has been approved for use in renal cell carcinomas since 
2007 in the EU140 and is mainly used as a first line treatment for patients with poor-risk 
disease, with increased aggressiveness and decreased prognosis. Phase III trial data 
has shown it improves median survival among this group178; however temsirolimus 
  
trials in breast cancer have produced inconclusive and the results are ‘mild’ at best. 
One phase II study found no objective response in the observed cohort, although the 
study size was small at only 31 patients179 and a separate phase II trial, using a larger 
cohort, showed a very modest response, with only 9.2% patients showing partial 
response to the drug138. Phase III trials of this drug combined with the aromatase 
inhibitor letrozole, in the HORIZON trials in post-menopausal women, again showed 
disappointing results and a lack of improved patient survival141. Interestingly, Rangwala 
and colleagues180 showed that combining a rapalogue like temsirolimus with the 
autophagy inhibitor hydroxychloroquine (HCQ), was well tolerated and showed anti-
tumor activity in melanoma patients, suggesting this may be a valuable area of 
exploration for breast cancer combination therapy in the future.  
 
Ridaforolimus: Although not currently approved for clinical use in cancer treatment, 
ridaforolimus has been explored in a number of trials for various cancer types including 
breast cancer. A phase II trial with ridaforolimus combined with trastuzumab, in HER-2 
positive, trastuzumab-refractory metastatic breast cancer patients, showed good anti-
tumor activity. The rate of response was similar to that with patients treated with first 
line trastuzumab, suggesting that a rapalogue like ridaforolimus may help overcome 
resistance to trastuzumab181. Phase II trials of ridaforolimus in endometrial cancer, 
refractory hematological cancers and soft and bone sarcomas has also shown some 
promising results in terms of anti-tumor activity, giving cause for possible further 
investigation142,182,183.  
 
Everolimus: In breast cancer, everolimus has shown many productive results, across a 
variety of clinical trials. As such, in 2012 everolimus (marketed as Afinitor) was 
approved for use in combination with the steroidal aromatase inhibitor exemestane in 
breast cancer patients with advanced cancer that is hormone receptor positive, HER-2 
negative (non-over-expressing), and whose prior treatment with a non-steroidal 
aromatase inhibitor (such as letrozole or anastrazole) had failed132,184,185. Key evidence 
for the use of everolimus in this subset of cancer patients came from the phase III 
BOLERO-2 (breast cancer trials of oral everolimus) clinical trial. This trial looked at the 
effect of combining everolimus with exemestane, in a subset of patients, where the 
cancer was refractory to non-steroidal aromatase inhibitors (all patients had received 
prior treatment with either letrozole or anastrazole). The patient set included those who 
had already been treated with one set of chemotherapy and/or hormonal therapy, and 
excluded patients who had already been treated with exemestane or other mTOR 
inhibitors. Patients treated with the combination of everolimus plus exemestane had a 
statistically significant increase in progression free survival (PFS), compared to 
exemestane and placebo treated patients; there was a PFS average of 2.8-4.1 months 
in the placebo arm compared 6.9-10.6 months in the everolimus arm of the trial. In 
terms of toxicity, the combination treatment was also well tolerated, according to 
quality of life (QOL) end-points and ECOG status186-188. These results are positive 
compared to the rather flat results of the HORIZON trial; both used a rapalogue in 
conjunction with an aromatase inhibitor, however it is possible that the use of a 
steroidal aromatase inhibitor (exemestane) enhanced the effects of the rapalogue in a 
greater way compared to its non-steroidal counter-part (letrozole). 
 
Rapalogues and drug-resistance: Since mTOR activation can often confer a resistance 
to trastuzumab119 it seems a viable option to use a rapalogue to increase patient 
sensitivity to this therapy once again. Phase II trial data validated this thinking, with 
results showing that patients on a regime of trastuzumab and paclitaxel (who had 
  
progressed whilst on trastuzumab treatment and were HER-2 positive) were showing 
increased PFS times and response rates to the therapy, with the weekly addition of 
everolimus189. However results from the phase III BOLERO-1 trial in a similar area were 
not as positive. The trial included patients with HER-2 positive (over-expressing) tumors 
with advanced disease who had not received chemotherapy (including trastuzumab) 
within the last 12 months. This time the addition of everolimus to trastuzumab and 
paclitaxel did not improve outcomes in a significant way although some small 
advantage to this treatment was noted in women who were hormone/ER receptor 
negative190. 
 
The BOLERO-3 phase III trial also studied women with advanced HER-2 positive cancers 
who were trastuzumab resistant and had previously received taxane treatment. The 
addition of everolimus to a regime of trastuzumab and vinorelbine increased PFS 
significantly, albeit by a small amount, compared to the placebo, group from a median 
of 5.78 months to 7 months. Again the sub-group of patients who were hormone 
receptor negative showed an increased efficacy of everolimus191. The data from the 
BOLERO-1 and 3 trials suggest that in HER-2 positive patients, hormone/ER receptor 
status may be key to everolimus efficacy. Since mTOR signaling can directly alter ER 
signalling112 and is a direct target of growth factor signaling like that of HER family 
receptors42, it is perhaps no surprise that these multiple pathways connect in relation to 
therapy efficacy. 
 
Considering the importance of selective estrogen receptor modulators (SERMs), the use 
of everolimus has also been explored in conjunction with tamoxifen. Phase II clinical 
trial data for this drug combination in post-menopausal advanced breast cancer 
patients who were HER-2 negative, hormone receptor positive and resistant to 
aromatase inhibitors, have been positive. Results suggested a significant increase in 
time to progression and overall clinical benefit192. A small phase II study in triple-
negative breast cancer patients showed that the combination of carboplatin and 
everolimus may have clinical benefit in this set of breast cancers193; however, the 
addition of everolimus to a regime of paclitaxel and bevacizumab was not shown to 
significantly increase efficacy of this combination drug regime194.  
 
Resistance to Rapalogues 
 
Whilst it is clear that the rapalogues have wide potential in the clinic, as in the case of 
everolimus use in breast cancer, they also are associated with key issues that may 
ultimately limit their application and range in terms of therapeutic use. Resistance to 
rapalogues (and a lack of efficacy to treatment) has been noted in many settings and 
can been caused by a host of factors. The inhibition of mTOR with rapalogues can alter 
feedback pathways that exist within PI3K-mTOR signaling as well as activate Akt 
signaling by shifting the burden of signaling towards mTORC232,172. This reduces the 
anti-cancer effects that rapalogues have195, and inhibition of Akt can directly re-
sensitize breast and colon cancer cells to rapalogue treatment, partially via increased 
inhibition of PRAS40 phosphorylation, increasing its inhibitory effect on mTORC1196. 
This same feedback effect on Akt has been noted in lung cancer cells where PI3K 
inhibition, again re-sensitized the cells to rapamycin treatment172. Since mTOR 
inhibition can activate apoptosis, a lack of functional apoptotic pathways can reduce 
their effectiveness as well195. Unsurprisingly, breast cancer cells with a higher 
reliance/activation of mTORC1 signaling, as shown by over-expression of 
phosphorylated S6K, show increased inhibition by rapalogues197. 
  
 
Many other signaling pathways and processes can affect and induce rapalogue 
resistance. For example MCF-7 breast cancer cells that have developed tamoxifen 
resistance are intrinsically resistant to everolimus198. Research suggests that 
expression of epithelial-mesenchymal transition (EMT) markers such as snail increase 
resistance to rapamycin, whilst expression of pre-EMT markers like E-cadherin increase 
breast cancer cell sensitivity to rapamycin, in vitro199. In breast cells (including the MCF-
7 cell line) that were induced to be everolimus resistant, MYC was suggested to play a 
role in the resistance process, as an up-regulation of MYC was seen in the resistant 
lines and depletion of MYC re-sensitized the cells to everolimus once more200. MCF-7 
cells treated with rapamycin also showed an up-regulation of transglutaminase 2 
(TGM2), seemingly as a compensatory mechanism, with TGM2 inhibition re-sensitizing 
cells to rapamycin201. Work with breast, colorectal and renal cancer cells also 
implicates Met to be involved a mechanism of rapalogue resistance, with increased Met 
activation conferring resistance202. Mutations could also induce rapalogue resistance 
breast cell lines; mutations in mTOR’s FRB domain (induced after long term rapamycin 
treatment) resulted in insensitivity to rapamycin, even over a period of weeks. Cells with 
this type of mutation are however still sensitive to ATP-competitive inhibitors of 
mTOR203.  
 
Alternatives to Rapalogues 
 
Inhibiting mTOR via FKBP12 is by no means the only way to achieve the overall effect of 
blocking mTOR activity. In fact there are now multiple, well explored, ways to block 
mTOR signaling, many of which circumnavigate the issues that arise with rapalogue 
use. Whilst these still present with their own issues, such as side effects, they have 
shown promising efficacy in the field of cancer treatment and early clinical trial stages 
and it is very possible that they will make their way into the clinical setting204.  
 
Unlike rapalogues that allosterically inhibit mTOR, ATP-competitive inhibitors block ATP 
binding and reduce the activity of both mTOR complexes. Due to the related sequence 
nature of mTOR (and other PIKK family proteins) and PI3K, many of the ATP 
competitive inhibitors also inhibit PI3K as well as mTOR. These inhibitors therefore 
reduce signaling across the entire PI3K-Akt-mTOR axis and reduce the problems of 
feedback activation to PI3K signaling or mTORC2 activation205. BEZ235 and PF-
04691502 are both dual PI3K-mTOR inhibitor of this class and have been studied for 
their anti-cancer efficacy in breast cancer. Both shown an anti-proliferative effect on 
cancer cells (and some tumors) and inhibition of PI3K-mTOR signalling206,207. However, 
since PI3K signaling controls such a broad range of downstream pathways and 
processes vital for a cell, inhibiting both PI3K and mTOR may have serious side effects 
that could limit the clinical application of such inhibitors. For example, in a phase II 
study of BEZ235 in pancreatic neuroendocrine patients who were everolimus resistant, 
the drug was poorly tolerated, limiting the trial progression208. 
 
More specific ATP-completive inhibitors, that only target mTOR, and thus block mTORC1 
and 2 are becoming more favorable. The drugs MLN0128, CC-223 and ADZ2014 have 
all shown promising results in terms of their anti-cancerous effects in breast cancer. 
AZD2014 and MLN0128 both show good anti-proliferative and anti-tumor effect in vitro 
and in vivo reducing signaling from mTORC1 and mTORC2, with MLN0128 also able to 
inhibit the growth of rapamycin-resistant breast cancer cells209-211. A phase I study of 
CC-223 has been relatively promising; it is well tolerated, with a partial response noted 
  
in a breast cancer patient, and disease stability in multiple types of cancer, as well as 
good inhibition of mTORC1 and 2 in patients209.  
 
Despite the issues of inhibiting PI3K, pan-PI3K inhibitors, such as the buparlisib 
(BKM120) have shown early promise in tackling breast cancers. Buparlisib widely 
inhibits PI3Ks but not does not directly inhibit mTOR; phase I data with buparlisib in 
combination with either trastuzumab212 or fulvestrant213 shows the drug to be well 
tolerated in breast cancer patients with some signs of disease management. PI3K 
inhibition may also be a viable way of avoiding resistance to rapalogues with buparlisib 
use, in combination with everolimus (or trastuzumab), reducing the occurrence of 
resistance to these drugs whilst also showing good growth inhibition, in vivo214.  
 
Inhibiting Akt directly is another alternative therapeutic option to rapalogues that has 
shown potential at a research stage and early clinical levels. In terms of breast cancer 
therapeutics, MK-2206, an allosteric inhibitor of Akt is perhaps the most promising of 
the selective Akt inhibitors. Multiple phase I trials have suggested this may hold key 
therapeutic benefit and it has been tested in a similar settings to the BOLERO trails. 
MK-2206 in combination with paclitaxel and trastuzumab, (similar to the BOLERO-1 
trial), was well tolerated, with 63% of patients showing a clinical response215. Likewise, 
MK-2206 in combination with anastrazole was also well tolerated and 42% of patients 
showed clinical benefit. Due to these successes, phase II trials are underway with MK-
2206216. Preclinical evidence for the efficacy of the ATP competitive inhibitor, 
AZD5363, is also positive, with breast cancers cells and xenografts showing some of 
the best responses to this drug of all malignancies tested217. 
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Rapalogue 
Side Chain 
(O- 
substitution 
on 
rapamycin 
at carbon 
40) Description Clinical uses References 
Everolimus 
(RAD-001) 
 
2-hydroxyl-ethyl 
side chain. 
Increased 
solubility over 
rapamycin, with 
bioavailability 
around 15% 
higher. 
Administered 
orally 
Approved for use in 
breast cancer, renal cell 
carcinoma and 
neuroendrocrine tumors 
of the pancreas, lungs or 
gut. Used for kidney 
transplants and tested in 
lung and heart 
transplants 
128,131-137 
Temsirolimus 
(CCI-779) 
 
Dihydroxymethyl-
propanoic acid 
side group. 
Increased 
solubility over 
rapamycin. 
Administered 
orally or IV 
Approved for use in renal 
cell carcinoma and 
mantle cell lymphoma. 
Tested at Phase II and III 
levels in breast cancer 
129,138-141 
Ridaforolimus 
(Deforolimus, 
AP23673) 
 
Phosphine-oxide 
side group. More 
soluble than 
rapamycin in 
water and 
organic solvents 
Phase II and III testing 
against sarcomas 
142,143 
Zotarolimus 
(ABT-578) 
 
Tetrazole side 
ring replacing 
hydroxyl group 
Inhibits growth of 
coronary smooth muscle 
cells and is used to treat 
stenosis in drug eluting 
stents 
124,144-146 
 
Table 1: Details, including clinical uses of the rapalogues; everolimus (RAD-001), 
temsirolimus (CCI-779), ridaforolimus (deforolimus, AB23573) and zotarolimus (ABT-
578). 
 
  
  
Figure Legends 
 
Figure 1: Basic structure of the 2549 residue protein, mTOR. The components of 
mTORC1 and 2 are marked as to which mTOR domain, or complex protein, they bind to. 
Components found in both complexes are marked in black, specific mTORC1 
components in grey and specific mTORC2 components in blue. Information: 11-
13,17,18,23,24. 
 
 
Figure 2: Common mutation hotspots along mTOR. Information: 108. 
 
 
Figure 3: Structure of rapamycin (sirolimus). Rapalogues vary from the parent 
rapamycin in mostly on one small side group. This occurs as an O-substitution at 
carbon-40 on rapamycin, underlined on the primary structure129,130. 
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